5752 RESULTS
Sort By:
Taos: New Neurons in New Mexico—Highlights from Keystone Taos: Disease, Drug Development, and Adult Neurogenesis It turns out you are not born with all the neurons you’ll ever need; adult neurogenesis is alive and kicking in the mammalian brain. Most ...
Keystone: Traumatic Brain Injury—Epidemiology and Characteristics Keystone: Sports-Related Injury and Chronic Traumatic Encephalopathy Keystone: Metabolic and Axonal Dysfunction in Traumatic Brain Injury Keystone: TBI—Learning From Markers, Models, and ...
San Francisco: Tweaking Brain ApoE Reduces Aβ, Symptoms San Francisco: GABA Neurons Blamed for Memory Loss in ApoE Mice Considering the dramatic impact of its E4 allelic variant on Alzheimer’s disease risk, apolipoprotein E arguably has drawn scant ...
NEALS: Collaboration for a Cure to ALS NEALS: In ALS Trials, One Design Does Not Fit All NEALS: Desperately Seeking ALS Biomarkers NEALS: Sharing Among ALS Researchers and Participants Starting on October 26, 2011, clinicians and some people with ...
Colombians Come to Fore in Alzheimer’s Research, Mass Media A Neurologist’s Devotion Puts Familial AD Research Onto New Plane Detecting Familial AD Ever Earlier: Subtle Memory Signs 15 Years Before Scientists and Regulators Discuss Preclinical AD Trials ...
Las Vegas: Lou Ruvo Center Pioneers New Approach to Clinical Trials Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma? Las Vegas: Can Collaboration Speed Drug Discovery for FTD? The Lou Ruvo Center for Brain Health opened in Las Vegas in 2009 ...
San Francisco: Gladstone Institute Hosts Tau Powwow San Francisco: Making Tau Toxic—Post-translational Changes Galore San Francisco: Is Tau Reduction a Good Thing? San Francisco: Tau—Time to Shine as Therapeutic Target? Tauists are having their heyday. ...
ADNI: One-year Data Narrow Field of MRI, FDG-PET Approaches ADNI: Mission Creep From Alzheimer Disease to Healthy Senior? Preliminary and mostly unpublished, analysis of one-year data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) is in! ...
From Australia, Impulse for a New Alzheimer’s Research Agenda Australia Report: Genetics and Aging Australia Report: Protein Aggregation, Selective Vulnerability, Spreading Australia Report: Aβ Toxicity, ApoE Australia Report: Inflammation Australia ...
DIAN Grows, Gets Ready for Therapeutic Trials DIAN: What Sayeth the Regulator? Q&A With Rusty Katz NIH Director Announces $100M Prevention Trial of Genentech Antibody Q&A With Ryan Watts, Genentech Lead Scientist on API Trial At the ...
St. Louis: Scientists, Families Target Preclinical Detection, Trials St. Louis: The Family View—What Do Study Volunteers Want From DIAN? St. Louis: Cognition Pre-dementia—Like eFAD, Like LOAD? St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD? St. ...
CSF Markers: Goodbye, Research Use Only; Hello, Clinical Metrology, Certification Heavies Take CSF Tests Under Their Wings The Global Consortium for the Standardization of CSF Biomarkers met in Vancouver, Canada, on 14 July 2012 to assess moves on two ...
Uppsala: Conference Puts Uppsala on Immunotherapy Map Uppsala: Is Tau Immunotherapy Taking Off? Uppsala: Immunotherapy—Not Just for AD Anymore Science has come a long way since botanist Carl Linnaeus built his catalogue and plant extracts were the ...
Eibsee: 8th Gathering of German-International Alzheimer’s Researchers Eibsee: Keynote on Anti-amyloid Drugs, Prevention Eibsee: Still Game for γ—Sparring With a Formidable Enzyme Eibsee: Channel Vanishes in Sharper Image Eibsee: Soft Cocktail—In Search of ...
Indianapolis: Frontotemporal Dementia Research Comes of Age Indianapolis: Neuroimaging Opens Window to Disease, Better Diagnosis Indianapolis: Dissecting the Pathways Behind Frontotemporal Dementia Indianapolis: Clinical Trials a Ripple, Scientists Hope ...
